EpiPen® information for healthcare professionals

Treating
anaphylaxis

Adrenaline is the drug of choice for the emergency treatment of severe allergic reactions to food, insect stings, medication, latex, exercise, and other allergens.

Read more

EpiPen®
explained

EpiPen® is an adrenaline auto-injector (AAI) used for self administration of adrenaline for the emergency treatment of severe allergic reactions (anaphylaxis).

Read more

Patient
support

We’re committed to supporting patients with anaphylaxis and have produced a number of resources to help.

Read more

Advice

Advice about the management of anaphylaxis, which recommends adrenaline as immediate first-line treatment.

READ MORE

EpiPen® Trainer Pen

How to use the EpiPen® Trainer and order a training kit.

READ MORE

The website you are trying to access is designed for healthcare professionals, the content is not designed for the general public.


Are you a healthcare professional registered in Ireland?

YES
NO

EpiPen® (adrenaline) and EpiPen® Junior (adrenaline) Auto-Injectors are indicated in the emergency treatment of severe allergic reactions (anaphylaxis) to insect stings or bites, foods, drugs and other allergens, as well as idiopathic or exercise induced anaphylaxis.

Product subject to medical prescription.

This site is designed for healthcare professionals registered in Ireland, if you are not a healthcare professional registered in Ireland, please
click here to visit our patient website.

For further information please consult:

EpiPen (adrenaline) 300 micrograms solution for injection in pre-filled pen, Summary of Product Characteristics

EpiPen Junior (adrenaline) 150 micrograms solution for injection in pre-filled pen, Summary of Product Characteristics

This website is owned and managed by Viatris.

@2023 Viatris. All rights reserved.

Viatris, Newenham Court, Northern Cross, Malahide Road, Dublin 17, Ireland.

Job Code: EPI-2023-0506
Date of Preparation: December 2023

Reporting of adverse reactions:

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.


Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system HPRA Pharmacovigilance, Website: www.hpra.ie


Adverse reactions/events should also be reported to the marketing authorisation holder at email address: pv.ireland@viatris.com or phone 0044 (0) 800 1218267.